The White House has reportedly stepped back from an executive order that would have created a council with the power to review and veto all National Institutes of Health (NIH) research grants, following public reports and bipartisan opposition in the Senate.
Senate resistance and a deadline of 11 December
News that the administration had abandoned the immediate plan came after Senate Appropriations Committee Chair Susan Collins (R‑ME) and Ranking Member Patty Murray (D‑WA) publicly opposed a proposed council that would place final authority over NIH awards into the hands of the Office of Management and Budget (OMB) director or his designees. The matter remains unresolved until the expiry of the current continuing resolution on 11 December, which has so far blocked a proposed OMB rule change that would have revised the Uniform Guidance to give political appointees wider control over federal grants.
In a letter to OMB Director Russell Vought and NIH Director Jay Bhattacharya, Ms Collins said the suggested council bore close similarity to the regulatory change that the continuing resolution had put on hold, and urged the White House to pursue any desired reforms through legislation rather than executive action.
Scientific community and White House responses
Scientific bodies, including the American Association for the Advancement of Science (AAAS), broadly opposed the council, which was first reported by news outlets rather than announced by the administration. A White House spokesperson told FYI that the administration “remains committed to the core mission of the NIH” and described the news reports as “baseless speculation.”
“remains committed to the core mission of the NIH” — White House spokesperson
The episode highlighted acute sensitivity in Congress and the research community to any perceived politicisation of grant-making. Critics warned that giving political appointees veto power over grant awards could undermine peer review and the independence of scientific judgement.
Related fiscal move draws criticism
Separately, late on Friday the White House announced a so‑called “pocket rescission” of $810 million in unspent federal funds, which included $28 million identified as Department of Health and Human Services research grant money. Ms Collins described the action as “a clear violation of the law.”
- $810 million — total unspent funds targeted in the pocket rescission.
- $28 million — portion reported to be HHS research grants.
- 11 December — date the continuing resolution expires, and when broader OMB rule changes could be reconsidered.
| Item | Detail |
|---|---|
| Oversight council | Would have given OMB director veto over NIH grants (reported proposal) |
| Legislative pause | Continuing resolution blocks related OMB rule until 11 December |
| Rescission | $810m total; $28m in HHS research grant funds |
The reported retreat does not close the question of executive influence over federal research funding entirely. The continuing resolution only temporarily restrains OMB’s ability to advance a rule that would alter the Uniform Guidance; any future attempt — whether by regulation or legislation — would be subject to renewed scrutiny in Congress and the scientific community.
For researchers and institutions that depend on NIH funding, the episode underscores a period of uncertainty. While the administration insisted its commitment to NIH’s mission remains intact, the combination of proposed oversight changes and the rescission of unspent funds will be closely watched for their potential to affect grant decisions, research programmes and the integrity of peer review.
In Washington, proponents of tighter executive oversight argue for accountability and better stewardship of public funds. Opponents counter that grant review must remain insulated from political interference to preserve scientific credibility and to ensure funding follows merit. With the continuing resolution in place until 11 December, the contest over how the United States organises and vets its biomedical research enterprise is set to continue.
